These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32457824)

  • 1. Biological Difference Between Epstein-Barr Virus Positive and Negative Post-transplant Lymphoproliferative Disorders and Their Clinical Impact.
    Ferla V; Rossi FG; Goldaniga MC; Baldini L
    Front Oncol; 2020; 10():506. PubMed ID: 32457824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent insights in the pathogenesis of post-transplantation lymphoproliferative disorders.
    Morscio J; Tousseyn T
    World J Transplant; 2016 Sep; 6(3):505-16. PubMed ID: 27683629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival.
    Kinch A; Baecklund E; Backlin C; Ekman T; Molin D; Tufveson G; Fernberg P; Sundström C; Pauksens K; Enblad G
    Acta Oncol; 2014 May; 53(5):669-79. PubMed ID: 24164103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders.
    Crombie JL; LaCasce AS
    Front Oncol; 2019; 9():109. PubMed ID: 30899698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surveillance of Epstein-Barr virus infection as a risk factor for post-transplant lymphoproliferative disorder in pediatric renal transplant recipients.
    Köpf S; Tönshoff B
    Pediatr Nephrol; 2004 Apr; 19(4):365-8. PubMed ID: 14963763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr Virus-Negative Diffuse Large B-Cell Post-transplant Lymphoma in an Epstein-Barr Virus-Positive Recipient.
    Lee C; Vincentelli H; Visuri J; Knight S; Ploeg R
    Cureus; 2021 Sep; 13(9):e18134. PubMed ID: 34567913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis.
    Capello D; Rossi D; Gaidano G
    Hematol Oncol; 2005 Jun; 23(2):61-7. PubMed ID: 16216037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
    Colombini E; Guzzo I; Morolli F; Longo G; Russo C; Lombardi A; Merli P; Barzon L; Murer L; Piga S; Ciofi Degli Atti ML; Locatelli F; Dello Strologo L
    Pediatr Nephrol; 2017 Aug; 32(8):1433-1442. PubMed ID: 28280938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA.
    Veltmaat N; Zhong Y; de Jesus FM; Tan GW; Bult JAA; Terpstra MM; Mutsaers PGNJ; Stevens WBC; Mous R; Vermaat JSP; Chamuleau MED; Noordzij W; Verschuuren EAM; Kok K; Kluiver JL; Diepstra A; Plattel WJ; van den Berg A; Nijland M
    J Hematol Oncol; 2023 Sep; 16(1):104. PubMed ID: 37705050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
    Mentzer SJ; Perrine SP; Faller DV
    Transpl Infect Dis; 2001 Sep; 3(3):177-85. PubMed ID: 11493400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
    Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
    Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1 Blockade Aggravates Epstein-Barr Virus
    Volk V; Theobald SJ; Danisch S; Khailaie S; Kalbarczyk M; Schneider A; Bialek-Waldmann J; Krönke N; Deng Y; Eiz-Vesper B; Dragon AC; von Kaisenberg C; Lienenklaus S; Bleich A; Keck J; Meyer-Hermann M; Klawonn F; Hammerschmidt W; Delecluse HJ; Münz C; Feuerhake F; Stripecke R
    Front Oncol; 2020; 10():614876. PubMed ID: 33511078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders.
    Fellner MD; Durand KA; Solernou V; Bosaleh A; Balbarrey Z; García de Dávila MT; Rodríguez M; Irazu L; Alonio LV; Picconi MA
    Rev Argent Microbiol; 2016; 48(2):110-8. PubMed ID: 27157146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-transplant lymphoproliferative disorders: role of viral infection, genetic lesions and antigen stimulation in the pathogenesis of the disease.
    Capello D; Gaidano G
    Mediterr J Hematol Infect Dis; 2009 Dec; 1(2):e2009018. PubMed ID: 21416004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease.
    Smets F; Latinne D; Bazin H; Reding R; Otte JB; Buts JP; Sokal EM
    Transplantation; 2002 May; 73(10):1603-10. PubMed ID: 12042647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular signature of Epstein Barr virus-positive Burkitt lymphoma and post-transplant lymphoproliferative disorder suggest different roles for Epstein Barr virus.
    Navari M; Fuligni F; Laginestra MA; Etebari M; Ambrosio MR; Sapienza MR; Rossi M; De Falco G; Gibellini D; Tripodo C; Pileri SA; Leoncini L; Piccaluga PP
    Front Microbiol; 2014; 5():728. PubMed ID: 25566237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
    Veloza L; Teixido C; Castrejon N; Climent F; Carrió A; Marginet M; Soldini D; González-Farré B; Ribera-Cortada I; Lopez-Guillermo A; González-Barca E; Sierra A; Herrera M; Gómez C; Garcia A; Balagué O; Campo E; Martinez A
    Histopathology; 2019 Dec; 75(6):799-812. PubMed ID: 30861172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
    Lee TC; Savoldo B; Barshes NR; Rooney CM; Heslop HE; Gee AP; Caldwell Y; Scott JD; Goss JA
    Clin Transplant; 2006; 20(3):389-93. PubMed ID: 16824159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.